NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 110
(Total Views: 49)
Posted On: 12/16/2024 3:55:26 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Eyes Clear Path Forward for Buntanetap
Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s (“AD”) and Parkinson’s (“PD”). The company concluded the third quarter with the completion of significant milestones and a clear path forward for its lead candidate, buntanetap. “Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43,” reads a recent article. “This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying, positioning buntanetap as a potential breakthrough in treating neurodegenerative diseases.”
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s (“AD”) and Parkinson’s (“PD”). The company concluded the third quarter with the completion of significant milestones and a clear path forward for its lead candidate, buntanetap. “Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43,” reads a recent article. “This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying, positioning buntanetap as a potential breakthrough in treating neurodegenerative diseases.”
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Anv Sec Group Inc. (ANVS) Stock Research Links
Scroll down for more posts ▼